WEBULL
News
HROWL
25.61
0.00%
0.00
Harrow Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Patrick William Sullivan
Reuters · 02/02 13:21
Harrow Reaffirms 2025 Revenue Guidance of $270–$280 Million
Reuters · 02/02 12:01
HARROW REAFFIRMS 2025 FULL-YEAR REVENUE GUIDANCE OF $270–$280 MILLION, MARKING ANOTHER YEAR OF STRONG GROWTH
Reuters · 02/02 12:00
Opaleye Management Inc. Reports Disposal of Harrow Inc. Common Shares
Reuters · 01/08 21:06
HARROW, INC. <HROW.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $69 FROM $64
Reuters · 11/12/2025 11:02
U.S. RESEARCH ROUNDUP-Floor & Decor Holdings, Composecure, Outfront Media
Reuters · 11/12/2025 07:18
Eye care drugmaker Harrow swings to Q3 profit
Reuters · 11/10/2025 21:23
Harrow Inc. reports third-quarter revenue of $71.6 million and net income of $1.0 million
Reuters · 11/10/2025 21:12
BRIEF-Harrow Inc Q3 Gross Margin 75%
Reuters · 11/10/2025 21:10
Weekly Report: what happened at HROWL last week (1006-1010)?
Weekly Report · 10/13/2025 09:34
Harrow Inc. Files Initial Statement of Beneficial Ownership for Francis William Mullery Jr., CEO of ImprimisRx
Reuters · 10/10/2025 22:23
HARROW INC - FRANK MULLERY APPOINTED AS CEO OF IMPRIMISRX
Reuters · 10/06/2025 11:00
Weekly Report: what happened at HROWL last week (0929-1003)?
Weekly Report · 10/06/2025 09:33
Harrow Inc. Issues Amendment to 8-K Report to File Merger Agreement with Melt Pharmaceuticals
Reuters · 10/01/2025 11:39
U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair
Reuters · 10/01/2025 07:33
HARROW INC <HROW.O>: B. RILEY RAISES TARGET PRICE TO $74 FROM $70
Reuters · 10/01/2025 02:59
HARROW INC - SECURES $40 MLN CREDIT FACILITY WITH $20 MLN INCREMENTAL LINE - SEC FILING
Reuters · 09/29/2025 11:03
Harrow Inc. Secures $40 Million Senior Secured Revolving Credit Facility with Fifth Third Bank, With Option for Additional $20 Million
Reuters · 09/29/2025 11:01
Weekly Report: what happened at HROWL last week (0922-0926)?
Weekly Report · 09/29/2025 09:34
BRIEF-Harrow To Buy Remaining Melt Equity For $4.3 Million Additional Consideration Upon Reaching Certain Milestones - SEC Filing
Reuters · 09/26/2025 11:09
More
Webull provides a variety of real-time HROWL stock news. You can receive the latest news about Harrow Health through multiple platforms. This information may help you make smarter investment decisions.
About HROWL
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.